NanoViricides, Inc. (NYSE American:NNVC), announced that it has entered into a securities purchase agreement with a single healthcare institutional investor for the purchase and sale of 3,571,429 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.68 per share in a registered direct offering. The gross proceeds from the Offering are expected to be approximately $6 million.
A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the offering. Lucosky Brookman served as counsel to the company.
